SCHEMBL5318943

SCHEMBL5318943

OCC=Cc1nn(Cc2ccc(Cl)cc2Cl)c2cc(OC(F)(F)F)ccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
PMP22 Q01453 1/20 0.40
HIF1A Q16665 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ENPP2 Q13822 2/20 0.39
TRPV1 Q8NER1 1/20 0.39
EPHX2 P34913 2/20 0.38
F2RL3 Q96RI0 3/20 0.38
MARS1 P56192 1/20 0.36
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NPC1 O15118 1/20 0.36
SLC16A3 O15427 2/20 0.36
SLC16A1 P53985 2/20 0.36
MCTS1 Q9ULC4 2/20 0.36
SLC9A1 P19634 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5318939 1.00 CYP1A2 (0.40) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL5348946 0.92 CYP1A2 (0.39) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL5348942 0.92 CYP1A2 (0.39) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL5317032 0.91 ENPP2 (0.40) CYP2D6CYP2C9ENPP2F2RL3MARS1
SCHEMBL5317033 0.91 ENPP2 (0.40) CYP2D6CYP2C9ENPP2F2RL3MARS1
SCHEMBL5359991 0.91 NPSR1 (0.38) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL5359999 0.91 NPSR1 (0.38) CYP1A2CYP3A4CYP2D6CYP2C9TSHR
SCHEMBL5317489 0.90 ENPP2 (0.38) CYP1A2CYP2D6CYP2C9ENPP2F2RL3
SCHEMBL5317486 0.90 ENPP2 (0.38) CYP1A2CYP2D6CYP2C9ENPP2F2RL3
SCHEMBL4093247 0.88 CYP2C9 (0.45) CYP1A2CYP3A4CYP2D6CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1786424-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT The University of Kansas (US) 2007-05-23 EP claimed
WO-2006023704-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT UNIVERSITY OF KANSAS (US) 2006-03-02 WO claimed
EP-2502624-A1 Lonidamine analogues and their use in male contraception and cancer treatment THE UNIVERSITY OF KANSAS (US) 2012-09-26 EP disclosed